Merck licenses innovative anti-cancer therapy LM-299 from LaNova Medicines

In a strategic move to broaden its oncology portfolio, Merck & Co., Inc. (NYSE: MRK), recognized globally as MSD outside the U.S. and Canada, has announced an exclusive licensing agreement with LaNova Medicines Ltd., a Shanghai-based biotech company. This agreement grants Merck the global rights to develop, manufacture, and commercialize LM-299, an investigational bispecific antibody targeting PD-1 and VEGF pathways. With a $588 million upfront payment and potential milestone earnings for LaNova reaching up to $2.7 billion, this collaboration is positioned as one of the year’s pivotal biotech deals.

Expanding Merck’s Oncology Pipeline

Dr. Dean Y. Li, president of Merck Research Laboratories, highlighted Merck’s commitment to advancing oncology treatments through robust partnerships and novel therapeutic mechanisms. Li expressed Merck’s enthusiasm for the addition of LM-299 to their oncology pipeline, emphasizing the company’s dedication to rigorously advancing innovative treatments for patients.

Financial Details and Milestone Potential

Under the terms, LaNova will receive an immediate payment of $588 million, while future performance-based milestones could raise LaNova’s total compensation to $2.7 billion. These milestones encompass stages of technology transfer, development, regulatory approvals, and successful commercialization across various potential indications for LM-299. The deal underscores Merck’s investment in cutting-edge oncology therapies and LaNova’s successful innovation in cancer treatment research.

Strategic Significance of LM-299: A Dual-Targeted Therapy

LM-299 is designed to simultaneously target PD-1 and VEGF pathways—two critical mechanisms implicated in cancer progression. By blocking PD-1/PD-L1 receptor signaling, LM-299 has the potential to unleash the body’s immune system against cancer cells while inhibiting VEGF-mediated angiogenesis, a process vital to tumor blood supply and growth. This bispecific approach represents a differentiated therapeutic strategy, with LM-299 currently in a Phase 1 clinical trial in China.

Leadership Perspective from LaNova Medicines

Dr. Crystal Qin, founder and CEO of LaNova Medicines, commended her team’s efforts in creating LM-299, expressing confidence in Merck’s capabilities to propel the antibody through advanced clinical stages. According to Qin, LaNova is steadfast in its mission to deliver impactful therapies globally by fostering partnerships and driving internal R&D initiatives.

Regulatory Approvals and Expected Transaction Close

The completion of this transaction is pending regulatory clearance, including approval under the Hart-Scott-Rodino Antitrust Improvements Act in the United States. Merck anticipates that the transaction will close by Q4 2024, with the company prepared to record the $588 million payment in its GAAP and non-GAAP results for the period. Merck has also indicated plans to disclose the earnings per share (EPS) impact following the transaction’s finalization.

Expert Insights: Potential Market Impact and Competitive Positioning

Industry analysts have noted that LM-299’s bispecific nature could offer a competitive advantage in the immuno-oncology market, particularly with an innovative mechanism addressing both immune checkpoint inhibition and angiogenesis. The strategic acquisition may enhance Merck’s positioning against other oncology leaders, especially as the company continues to diversify its portfolio amidst heightened market competition and evolving cancer treatment paradigms.